Price$8.91+0.15 (+1.71%)
01:30 PM04:45 PM
News · 26 weeks51-78%
2025-12-142026-06-07
Mix1490d
- SEC Filings7(50%)
- Other5(36%)
- Earnings2(14%)
Latest news
25 items- SECCorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CorMedix Inc. (0001410098) (Filer)
- PRU.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent LitigationPARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that the patents covering its product MINOCIN® for Injection are valid and infringed by the product developed by Nexus Pharmaceuticals, Inc. Following a four-day bench trial in 2023, the district court found in favor of CorMedix's wholly owned subsidiary Melinta Therapeutics on all patent infringement and validity issues. The Federal Circuit's decision on Friday upheld the district court's findings that Nexus' proposed generic minocyc
- PRCormedix Therapeutics to Participate in two Upcoming Investor ConferencesPARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026 and the Jefferies Global Healthcare Conference being held in New York on June 2 – 4, 2026. Details for each fireside chat is as follows: RBC Capital Markets Global Healthcare Conference Date:Wednesday, May 20, 2026Time:11:00am EDTWebcast:Click here Jefferies Global Healthcare Conference Date:Wednesday, June 3, 2026Time:4:20pm EDTWebcast:Click here About CorMedix CorMedix Therapeutics is a biopharmaceu
- SECSEC Form 10-Q filed by CorMedix Inc.10-Q - CorMedix Inc. (0001410098) (Filer)
- SECCorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CorMedix Inc. (0001410098) (Filer)
- PRCormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced financial results for the first quarter ended March 31, 2026 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $127.4 million of net revenue for the first quarter of 2026, reflecting strong first quarter execution and positive underlying demand trends. The Company also recognized net income of $38.6 mill
- PRCorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 14, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, May 14th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Webcast:Webcast Link About CorMedixCorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing product
- SECSEC Form DEFA14A filed by CorMedix Inc.DEFA14A - CorMedix Inc. (0001410098) (Filer)
- SECSEC Form DEF 14A filed by CorMedix Inc.DEF 14A - CorMedix Inc. (0001410098) (Filer)
- SECCorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CorMedix Inc. (0001410098) (Filer)
- PRCorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related discontinuations and drug-drug interactions – – Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens – PARSIPPANY, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (H
- SECSEC Form PRE 14A filed by CorMedix Inc.PRE 14A - CorMedix Inc. (0001410098) (Filer)
- PRCorMedix to Participate in Needham Virtual Healthcare ConferencePARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming 25th Annual Needham Virtual Healthcare Conference taking place April 13 – 16, 2026. 25th Annual Needham Virtual Healthcare ConferenceDate: April 14, 2026Time: 3:00pm EasternFormat: Fireside ChatWebcast: Link to webcast About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic produ
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CorMedix Inc.SCHEDULE 13G/A - CorMedix Inc. (0001410098) (Subject)
- SECCorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CorMedix Inc. (0001410098) (Filer)
- SECSEC Form 10-K filed by CorMedix Inc.10-K - CorMedix Inc. (0001410098) (Filer)
- SECCorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CorMedix Inc. (0001410098) (Filer)
- PRCorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $128.6 million of net revenue for the fourth qu
- PRCorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, March 5th @ 8:30am ETDomestic: 1-844-676-2922International: 1-412-634-6840Webcast: Webcast Link About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializi
- PRCorMedix to Participate in Upcoming Investor ConferencesBERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March. Leerink Partners Global Healthcare ConferenceDate: March 10, 2026Time: 1:00pm EasternFormat: Fireside ChatWebcast: Link to webcast Citizens Life Sciences ConferenceDate: March 11, 2026Time: 9:35am EasternFormat: Fireside ChatWebcast: Link to webcast Barclays 28th Annual Global Healthcare ConferenceDate: Marc
- INSIDERChief Legal Officer Zelnick Kaufman Beth was granted 36,006 shares, increasing direct ownership by 15% to 269,108 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERChief Executive Officer Todisco Joseph was granted 77,156 shares, increasing direct ownership by 11% to 774,749 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERChief Operating Officer Hurlburt Elizabeth was granted 36,006 shares, increasing direct ownership by 15% to 278,539 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- PRCorMedix Therapeutics Announces Share Repurchase ProgramBERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company's outstanding common stock. The repurchase program is authorized through December 31, 2027. "With a strong balance sheet, solid operating performance, and expected ongoing cash flow generation, we believe we are well positioned to execute this share repurchase program while continuing to advance our growth s
- PRCorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern. The Company will share background and updates across its portfolio and pipeline, and outline the business' key growth drivers and upcoming milestones. The event will feature key opinion leaders who will join members of the Company's senior management team, offering insights into evolving
CRMD FAQ
6 questionsWhat does CorMedix Inc. do?
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton...Where does CRMD stock trade?
CorMedix Inc. (CRMD) is listed on AMEX.What sector and industry is CRMD in?
CorMedix Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CRMD?
CorMedix Inc. has had 7 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $1400.00 price target on 2025-10-20. Recent price targets range from $600.00 to $2000.00.What companies are similar to CRMD?
Notable peers in the same industry include NEXT (NextDecade Corporation), OUST (Ouster Inc.), PRVB (Provention Bio Inc.). Compare CRMD side-by-side with any of them on Quantisnow.How can I track CRMD on Quantisnow?
Quantisnow aggregates CorMedix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRMD to receive live email and push alerts on every new disclosure.